ADELAIDE, Australia / RankWire.AI / – In Australia, researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a new molecular switch involved in the progression of aggressive tumors. Their findings, published in EMBO Molecular Medicine, reveal a promising approach to address triple-negative breast cancer by restoring the function of a key regulatory molecule called miR-342. This breakthrough paves the way for new strategies to prevent deadly secondary cancers in organs such as the lungs and bones.
Although triple-negative breast cancer represents 10% to 15% of Australia’s roughly 21,000 annual breast cancer cases, it accounts for a disproportionate share of fatalities. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, making standard hormone-targeted treatments ineffective. The lead researchers demonstrated that when miR-342 levels decrease, a cancer-promoting pathway named E2F becomes overly active, enabling dormant cancer cells to metastasize and form dangerous secondary tumors throughout the body.
Potential for Diagnostic Biomarker Testing to Identify High-Risk Patients
In pre-clinical experiments, scientists showed that increasing miR-342 levels significantly reduced the spread of cancer cells to distant organs. They also found that palbociclib, an existing CDK4/6 inhibitor drug approved for hormone receptor-positive cancers, substantially slowed metastatic tumor growth in models with low miR-342 levels. These results suggest that testing for miR-342 could enable clinicians to repurpose current treatments for patients at high risk of metastasis.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, a co-senior author, emphasized that preventing metastasis remains the main hurdle in treating aggressive breast cancers. Gregory highlighted that since palbociclib targets the hyperactive E2F pathway, administering it after cancer has spread can prevent microscopic deposits from expanding. Instead of focusing solely on reducing primary tumors, this approach aims to stop tiny secondary cancers from developing into life-threatening conditions.
miR-342 as a Master Regulator in Cancer-Related Genes
The research team pointed out that the biological diversity of triple-negative breast cancer has long complicated the development of universal targeted therapies. By identifying a specific biological vulnerability shared by a certain patient subgroup, this study opens new possibilities for personalized treatment strategies. As Australian researchers work to validate these findings with patient-derived models, efforts are underway before moving into clinical trial phases.
Medical oncologists and cancer research institutions across Australia expressed enthusiasm for these discoveries, emphasizing the urgent need for expanded treatment options when primary therapies prove insufficient. The research team intends to partner with international clinical networks to fast-track biomarker screening methods. Confirming the usefulness of miR-342 testing could soon help clinicians identify suitable candidates for targeted CDK4/6 inhibitor therapies during early treatment stages.